By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...

Gaithersburg’s Novavax has struck a deal to give Pfizer the rights to its adjuvant technology — for a potential $530 million ...

Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to ...

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Novavax’s president and CEO reviewed the company’s successes in 2025 and shared its growth strategy for 2026 and beyond at a ...

Pfizer will now employ Novavax’s adjuvant, Matrix-M, into its vaccines across two disease areas.

Novavax entered the 2026 J.P. Morgan Healthcare Conference positioning itself as a partner-driven company focused on ...

Novavax, Inc. has entered into a license agreement with Pfizer for use of Novavax's Matrix-M® adjuvant. Under the terms of ...

Sweeping U.S. policy changes under Health Secretary Robert F. Kennedy Jr. are having a ‌chilling effect ​on vaccine makers as ...

The unprecedented changes have led to diminished vaccine usage, and created a drag that will likely dent revenues.

Recent health sector developments highlight Moderna and Merck's promising skin cancer vaccine trial alongside China's declining birthrate, and significant business moves from pharmaceuticals giants ...